title: Case-control study of aspirin use and risk of pancreatic cancer.
abstract: BACKGROUND
  Pancreas-cancer prognosis is dismal, with 5-year survival less than 5%. Significant relationships between aspirin use and decreased pancreas-cancer incidence and mortality have been shown in four of 13 studies.
  
  
  METHODS
  To evaluate further a possible association between aspirin use and risk of pancreatic cancer, we used data from a population-based Connecticut study conducted from January 2005 to August 2009, of 362 pancreas-cancer cases frequency matched to 690 randomly sampled controls.
  
  
  RESULTS
  Overall, regular use of aspirin was associated with reduced risk of pancreatic cancer [odds ratio (OR), 0.52; 95% confidence interval (CI), 0.39-0.69]. Increments of decreasing risk of pancreatic cancer were observed for each year of low-dose or regular-dose aspirin use (OR, 0.94; 95% CI, 0.91-0.98 and OR, 0.98; 95% CI, 0.96-1.01, respectively) and for increasing years in the past that low-dose or regular-dose aspirin use had started (OR, 0.95; 95% CI, 0.92-0.99 and OR, 0.98; 95% CI, 0.96-1.00, respectively). Reduced risk of pancreatic cancer was seen in most categories of calendar time period of aspirin use, for both low-dose aspirin and regular-dose aspirin use. Relative to continuing use at the time of interview, termination of aspirin use within 2 years of interview was associated with increased risk of pancreatic cancer (OR, 3.24; 95% CI, 1.58-6.65).
  
  
  CONCLUSIONS
  Our results provide some support that a daily aspirin regimen may reduce risk of developing pancreatic cancer.
  
  
  CONCLUSIONS
  Long-term aspirin use has benefits for both cardiovascular disease and cancer, but appreciable bleeding complications that necessitate risk-benefit analysis for individual applications.
authors: Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of Public Health;
authors: Samantha A
authors: SA
authors: Streicher
authors: Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
authors: Herbert
authors: H
authors: Yu
authors: Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of Public Health;
authors: Lingeng
authors: L
authors: Lu
authors: Department of Surgery, Yale School of Medicine, New Haven, Connecticut; and.
authors: Mark S
authors: MS
authors: Kidd
authors: Authors' Affiliations: Department of Chronic Disease Epidemiology, Yale School of Public Health; harvey.risch@yale.edu.
authors: Harvey A
authors: HA
authors: Risch
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010190:Pancreatic Neoplasms / Q000453:epidemiology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin